Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Pricing Pressure? Recordati Continues Push Into Turkey With Latest Acquisition

This article was originally published in PharmAsia News

Executive Summary

Although many pharma companies are reducing investments in Turkey after a series of controversial government price cuts, Italian drug maker Recordati S.p.A is doing just the opposite, buying Istanbul-based Dr. F. Frick Ilac for $130 million earlier this month, its second acquisition in Turkey in three years. Recordati, in fact, sees significant growth opportunities in Turkey and Eastern European, and says more deals could be on the way

You may also be interested in...



Italy’s Recordati Starts $50 Million Greenfield Investment In Turkey

Italian pharmaceutical company Recordati invests $50 million in Turkey to establish a production facility in Tekirdag province to produce cardiovascular drugs.

Earnings Briefs: Actavis, Celgene, InterMune, Lilly, Forest

Companies are reporting out their half-year earnings and giving investors updates on the progress of their pipelines, as well as ongoing launch plans. Actavis and Warner Chilcott are in line as their merger approaches; Lilly’s Lechleiter gives an update on BD plans; AbbVie talks about its HCV combo; and Shire recommits to ADHD promotion.

Amgen Shrugs Off Turkish Price Cuts, Snatches Up Mustafa Nevzat For Broader Reach Into Emerging Markets

Despite harsh price cuts in Turkey that have taken a toll on multinationals, Amgen dives head first into the market.

Related Content

UsernamePublicRestriction

Register

SC078481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel